drugset / Trial / NCT00318344

Evaluation of Atuna Racemosa Toxicity

NCT00318344 ↗

Phase 1 Completed 20 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelTreatment

Summary

For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled clinical trial to evaluate toxicity has never been performed.

Timeline

Start
2006-04
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atuna Racemosa Traditional medicine (herbal / TCM) — Topical